Cannabis Has No Proven Role in Treating Meningitis, Though CBG Shows Early Antibacterial Potential
Meningitis is inflammation of the protective membranes surrounding the brain and spinal cord. It can result from bacterial, viral, fungal or other causes, and bacterial meningitis is a medical emergency that may worsen within hours. Complications can include seizures, hearing loss, brain injury, kidney problems, limb loss and death.
Symptoms may include fever, headache, stiff neck, nausea, vomiting, sensitivity to light and confusion. Infants may instead be unusually sleepy or irritable, feed poorly, vomit or develop a bulging soft spot on the skull. Anyone with possible meningitis symptoms should seek urgent medical care; cannabis products should not be used as a substitute for diagnosis or treatment.
Vaccination remains one of the most effective ways to prevent several forms of bacterial meningitis. The Centers for Disease Control and Prevention’s overview of bacterial meningitis identifies Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae type b among the important bacterial causes and notes that pneumococcal, meningococcal and Hib vaccines help protect against them.
The research sometimes cited in connection with cannabis and meningitis does not show that medical cannabis treats meningitis. In a 2020 study published in ACS Infectious Diseases, researchers led by Eric Brown at McMaster University screened cannabinoids for antibacterial activity. They focused on cannabigerol, or CBG, a non-intoxicating cannabinoid that showed activity against methicillin-resistant Staphylococcus aureus in laboratory experiments and in a mouse model of systemic infection.
The researchers also reported that CBG could work against certain Gram-negative bacteria when their protective outer membrane was disrupted with polymyxin B. That finding suggests a possible starting point for antibiotic development, particularly against drug-resistant organisms. However, the experiments were primarily laboratory and animal research. They did not demonstrate that CBG prevents or treats meningitis, nor did they establish a safe or effective dose for people. The study also identified toxicity to host cells as an important limitation.
Cannabinoids have been investigated for their effects on inflammation and immune signaling. Research reviews describe activity involving cannabinoid receptors such as CB1 and CB2, but these effects are complex and may vary by cannabinoid, dose, tissue and disease. Reducing inflammation is not the same as eliminating the infection that causes bacterial meningitis; in some infections, altering immune responses could be harmful.
For now, the connection between cannabis and meningitis is therefore indirect. CBG and other cannabinoids may eventually contribute to new antimicrobial medicines, but the available evidence does not support using cannabis or CBG to treat meningitis. Suspected bacterial meningitis requires prompt clinical evaluation, appropriate antibiotics and other hospital-based care. Prevention through recommended vaccination and rapid medical attention remain the established strategies.
